I kliniske studier inden for alle indikationer spændte hyppigheden af NCI- CTC grad 3- 5 blødninger fra 0, 4% – 5% for de Avastin- behandlede patienter, og for de patienter, der fik kemoterapi alene, var hyppigheden 2, 9%.
In clinical trials across all indications the overall incidence of NCI-CTC Grade 3-5 bleeding events ranged from 0.4% to 5% in Avastin treated patients, compared with up to 2.9% of patients in chemotherapy control group.